Document is current
Any future updates will be listed below
-
Authors
Schonhoff, A. M. http://orcid.org/0000-0002-1801-1125
Figge, D. A.
Williams, G. P. http://orcid.org/0000-0001-9523-1781
Jurkuvenaite, A. http://orcid.org/0000-0002-9193-5797
Gallups, N. J. http://orcid.org/0000-0003-0820-0085
Childers, G. M. http://orcid.org/0000-0003-1195-4750
Webster, J. M. http://orcid.org/0000-0001-8230-6174
Standaert, D. G. http://orcid.org/0000-0003-2921-8348
Goldman, J. E. http://orcid.org/0000-0003-2135-8936
Harms, A. S. http://orcid.org/0000-0002-7054-2812
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (5 F31 NS106722-02, R01NS107316)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
- License Information
-
More Information
Article History
Received: 19 October 2022
Accepted: 26 May 2023
First Online: 26 June 2023
Competing interests
: Dr. Standaert has served as a consultant for or received honoraria from Abbvie Inc., Curium Pharma, Appello, Theravance, Sanofi-Aventis, Alnylam Pharmaceutics, Coave Therapeutics, BlueRock Therapeutics, and F. Hoffman-La Roche. All remaining authors declare no competing interests.
